Cargando…

Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies

T cell immune protection plays a pivotal role in the treatment of patients with hematological malignancies. However, T cell exhaustion might lead to the possibility of immune escape of hematological malignancies. Adoptive cell therapy (ACT) with chimeric antigen receptor T (CAR-T) cells can restore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yan, Weiqi, Liu, Zhuojun, Liu, Jia, Xia, Yuanshi, Hu, Kai, Yu, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547336/ https://www.ncbi.nlm.nih.gov/pubmed/33062678 http://dx.doi.org/10.1155/2020/4241864

Ejemplares similares

Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies
por: Han, Yizhao, et al.
Publicado: (2020)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies
por: Shen, Chunyi, et al.
Publicado: (2020)

A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination
por: Liu, Jia, et al.
Publicado: (2021)

Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
por: Yang, Zhihuan, et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Chimeric antigen receptor T cells self-neutralizing IL6 storm in patients with hematologic malignancy
por: Xue, Lei, et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
por: Guo, Zhenling, et al.
Publicado: (2021)

Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies
por: Wang, Haobing, et al.
Publicado: (2023)

Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience
por: Sun, Wei, et al.
Publicado: (2023)

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies
por: Xie, Bailu, et al.
Publicado: (2022)

Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies
por: Xie, Danni, et al.
Publicado: (2022)

The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead
por: Rohit Reddy, Sai, et al.
Publicado: (2021)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review
por: Hanna, Kerollos S, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review
por: Efficace, Fabio, et al.
Publicado: (2022)

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis
por: Luo, Wenjing, et al.
Publicado: (2022)

Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018)

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
por: Roex, Gils, et al.
Publicado: (2020)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
por: Keshavarz, Ali, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis
por: Yu, Wen-Liang, et al.
Publicado: (2019)

Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies
por: Polgárová, Kamila, et al.
Publicado: (2022)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

CD38 as a pan-hematologic target for chimeric antigen receptor T cells
por: Glisovic-Aplenc, Tina, et al.
Publicado: (2023)

The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study
por: Dong, Rujiao, et al.
Publicado: (2022)

Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review on comparative studies
por: Saiz, Luis Carlos, et al.
Publicado: (2023)

Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials
por: Ormhøj, Maria, et al.
Publicado: (2022)

Chimeric antigen receptor T cells for gamma–delta T cell malignancies
por: Wawrzyniecka, P. A., et al.
Publicado: (2021)

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy
por: Zhang, Leqiang, et al.
Publicado: (2022)

Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future
por: Heine, Renaud, et al.
Publicado: (2021)

Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
por: Drokow, Emmanuel Kwateng, et al.
Publicado: (2019)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells
por: Maher, John
Publicado: (2012)

Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
por: Totzeck, Matthias, et al.
Publicado: (2022)

Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
por: Collinson-Pautz, Matthew R., et al.
Publicado: (2019)

A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies
por: Liu, Jia, et al.
Publicado: (2020)

Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
por: Ying, Zhitao, et al.
Publicado: (2021)

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
por: Jin, Ke-Tao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d7bhgnn80jb748jhle9qhhp2qd